Association of Ground Glass Opacities with Systemic Inflammation and Progression of Emphysema

By sjmartinez • June 7, 2024

Fortis S, Guo J, Nagpal P, Chaudhary MFA, Newell JD Jr, Gerard SE, Han MK, Kazerooni EA, Martinez FJ, Barjaktarevic IZ, Barr RG, Bodduluri S, Paine Iii R, Awan HA, Schroeder JD, Gravens-Mueller LD, Ortega VE, Anderson WH, Cooper CB, Couper D, Woodruff PG, Bowler RP, Bhatt SP, Hoffman EA, Reinhardt JM, Comellas AP. Association of Ground Glass Opacities with Systemic Inflammation and Progression of Emphysema. Am J Respir Crit Care Med. 2024 Jun 6. doi: 10.1164/rccm.202310-1825OC. Epub ahead of print. PMID: 38843116.

Tags: COPD, emphysema, ground glass opacity, Inflammation, Publications, Pulmonary, Critical Care & Sleep Medicine

First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial

Sun JM, Chao Y, Kim SB, Rha SY, Evans TRJ, Strickland AH, Wainberg Z, Chau I, Pelles-Avraham S, Ajani J, Malhotra R, Liu Q, Li[...]

Drug Development

Cole GM, Zhu C, Manglani K, Hou K, Bombino A, Jones M, Eisenberg DS, Frautschy SA. Drug Development. Alzheimers Dement. 2025 Dec;21 Suppl 5:e106249. doi:[...]

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study

Pistilli B, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Jañez NM, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E,[...]